Compare INMB & HUIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMB | HUIZ |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 31.5M |
| IPO Year | 2018 | 2019 |
| Metric | INMB | HUIZ |
|---|---|---|
| Price | $1.33 | $1.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.30 | $2.30 |
| AVG Volume (30 Days) | ★ 408.0K | 2.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,000.00 | N/A |
| Revenue This Year | $264.29 | $22.67 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | ★ N/A | $7.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.21 | $1.50 |
| 52 Week High | $11.64 | $4.16 |
| Indicator | INMB | HUIZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 39.15 |
| Support Level | $1.21 | $1.60 |
| Resistance Level | $1.71 | $2.19 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 19.24 | 49.49 |
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.